NASDAQ:PROF Profound Medical (PROF) Stock Price, News & Analysis $5.48 -0.10 (-1.79%) As of 02:38 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Profound Medical Stock (NASDAQ:PROF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Profound Medical alerts:Sign Up Key Stats Today's Range$5.50▼$5.6650-Day Range$5.23▼$6.7952-Week Range$3.89▼$10.25Volume7,627 shsAverage Volume65,839 shsMarket Capitalization$164.67 millionP/E RatioN/ADividend YieldN/APrice Target$11.00Consensus RatingBuy Company Overview Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada. Read More Profound Medical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScorePROF MarketRank™: Profound Medical scored higher than 37% of companies evaluated by MarketBeat, and ranked 1440th out of 1,841 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingProfound Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageProfound Medical has only been the subject of 1 research reports in the past 90 days.Read more about Profound Medical's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Profound Medical are expected to grow in the coming year, from ($1.12) to ($0.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Profound Medical is -4.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Profound Medical is -4.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProfound Medical has a P/B Ratio of 2.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Profound Medical's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.04% of the outstanding shares of Profound Medical have been sold short.Short Interest Ratio / Days to CoverProfound Medical has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.Change versus previous monthShort interest in Profound Medical has recently increased by 0.38%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProfound Medical does not currently pay a dividend.Dividend GrowthProfound Medical does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.04% of the outstanding shares of Profound Medical have been sold short.Short Interest Ratio / Days to CoverProfound Medical has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.Change versus previous monthShort interest in Profound Medical has recently increased by 0.38%, indicating that investor sentiment is decreasing. News and Social Media0.6 / 5News SentimentN/A Search Interest1 people have searched for PROF on MarketBeat in the last 30 days. Company Ownership2.5 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Profound Medical insiders have bought more of their company's stock than they have sold. Specifically, they have bought $100,201.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 1.52% of the stock of Profound Medical is held by insiders.Percentage Held by Institutions47.86% of the stock of Profound Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Profound Medical's insider trading history. Receive PROF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Profound Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address PROF Stock News HeadlinesProfound Medical to Announce Q2 2025 Financial ResultsJuly 24, 2025 | tipranks.comProfound Medical to Release Second Quarter 2025 Financial Results on August 14 – Conference Call to FollowJuly 24, 2025 | financialpost.comFAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. While the crowd buys Bitcoin outright, trader Larry Benedict is using a method called “Bitcoin Skimming” to target 6x, 9x, even 22x bigger profits. He reveals how it works in a free video.August 6 at 2:00 AM | Brownstone Research (Ad)Profound Medical to Release Second Quarter 2025 Financial Results on August 14 – Conference Call to FollowJuly 24, 2025 | globenewswire.com'Profound Sadness': Colleagues, Friends Mourn Beloved East End Doctor Who Died During TriathlonJuly 17, 2025 | msn.comProfound Medical Completes First Commercial BPH Treatment With New TULSA-AI Volume Reduction ModuleJune 25, 2025 | msn.comWexford family with ‘profound medical needs’ removed from choice-based letting system as council accused of lacking ‘humanity’June 16, 2025 | msn.comFamed Former NFL Safety, Leonard Wheeler, Named Global Ambassador For TULSA-PRO®June 4, 2025 | financialpost.comFSee More Headlines PROF Stock Analysis - Frequently Asked Questions How have PROF shares performed this year? Profound Medical's stock was trading at $7.51 at the beginning of 2025. Since then, PROF shares have decreased by 26.1% and is now trading at $5.55. How were Profound Medical's earnings last quarter? Profound Medical (NASDAQ:PROF) released its quarterly earnings results on Thursday, May, 8th. The company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by $0.07. The business earned $2.62 million during the quarter, compared to the consensus estimate of $4.78 million. Profound Medical had a negative net margin of 269.35% and a negative trailing twelve-month return on equity of 70.41%. Read the conference call transcript. Who are Profound Medical's major shareholders? Profound Medical's top institutional investors include Gagnon Securities LLC (5.82%), Timelo Investment Management Inc. (2.80%) and Ring Mountain Capital LLC (1.19%). View institutional ownership trends. How do I buy shares of Profound Medical? Shares of PROF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Profound Medical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Profound Medical investors own include Alibaba Group (BABA), Pfizer (PFE), NVIDIA (NVDA), PayPal (PYPL), Tesla (TSLA) and Docusign (DOCU). Company Calendar Last Earnings5/08/2025Today8/06/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryMedical Equipment Current SymbolNASDAQ:PROF CIK1628808 Webwww.profoundmedical.com Phone(647) 476-1350Fax64-7847-3739Employees150Year FoundedN/APrice Target and Rating Average Price Target for Profound Medical$11.00 High Price Target$11.00 Low Price Target$11.00 Potential Upside/Downside+97.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($1.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$27.82 million Net Margins-269.35% Pretax Margin-269.38% Return on Equity-70.41% Return on Assets-57.22% Debt Debt-to-Equity Ratio0.09 Current Ratio11.31 Quick Ratio10.03 Sales & Book Value Annual Sales$10.68 million Price / Sales15.70 Cash FlowN/A Price / Cash FlowN/A Book Value$2.01 per share Price / Book2.78Miscellaneous Outstanding Shares30,050,000Free Float29,596,000Market Cap$167.68 million OptionableOptionable Beta0.52 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:PROF) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredGuess Who the Gvt Could Partner With Next?The Government Just Made a $400M Bet. Who's Next? A $100 trillion wealth shift is quietly underway... and t...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredAltucher: $900 to $108,000? Trump’s “Great Gain” Is HereJames Altucher says two recent events could trigger a historic wealth shift—one driven by a radical Trump poli...Paradigm Press | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Profound Medical Please log in to your account or sign up in order to add this asset to your watchlist. Share Profound Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.